{{medical}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444377257
| IUPAC_name = (4''S'')-3-[(2''S'')-2-<nowiki>{</nowiki>[(2''S'')-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino<nowiki>}</nowiki>propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
| image = Imidapril structure.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|imidapril}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 89371-37-9
| ATC_prefix = C09
| ATC_suffix = AA16
| ATC_supplemental =  
| PubChem = 5464343
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = BW7H1TJS22
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08068
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4576628
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 317094
|  smiles = O=C(O)[C@H]2N(C(=O)[C@@H](N[C@H](C(=O)OCC)CCc1ccccc1)C)C(=O)N(C)C2
|  InChI = 1/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
|  InChIKey = KLZWOWYOHUKJIG-BPUTZDHNBX
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = KLZWOWYOHUKJIG-BPUTZDHNSA-N

<!--Chemical data-->
| chemical_formula =  
| C=20 | H=27 | N=3 | O=6 
| molecular_weight = 405.444 g/mol
}}

'''咪达普利'''（{{lang-en|Imidapril|}}）商品名：'''达爽'''，是一款[[血管紧张素转化酶抑制剂|血管紧张素转化酶抑制剂]][[抗高血压药|抗高血压药]]物，在1993年由日本[[田边制药|田边制药]]研制并投入市场。<ref>{{cite Web|author=田边制药|url=http://www.tanabe.com.cn/000173369.shtml.htm|title=达爽|date=2011-02-06|accessdate=2011-02-06|archive-date=2009-12-21|archive-url=https://web.archive.org/web/20091221194403/http://www.tanabe.com.cn/000173369.shtml.htm|dead-url=yes}}</ref>

咪达普利口服后，在体内转换成活性代谢物咪达普利拉（Imidaprilat）。咪达普利拉可抑制血管紧张素转化酶活性，阻止血管紧张素I向血管紧张素II的转化，使外周血管舒张，降低血管阻力，产生降压作用。成人服用量为每日5~10mg。

== 副作用 ==
咪达普利不良反应有低血压、头痛、咽部不适、皮疹、咳嗽；偶有伴呼吸困难的血管神经性水肿、肝肾功能损害、血象异常。对服用其他ACEI曾引起血管神经性水肿的患者以及妊娠妇女禁用。

== 药物相互作用 ==
=== 药物配伍禁忌 ===
* 葡萄糖硫酸纤维素吸附器进行LDL治疗
** 可能引起休克
* 丙烯酸腈甲烯丙基磺酸钠膜(AN69)进行血液透析
** 可能发生过敏症状

== 药物分类 ==
* ATC：C09AA16
* [[血管紧张素转换酶抑制剂|血管紧张素转换酶抑制剂]]
* [[循环系统药物|循环系统药物]]

==参考资料==
{{reflist}}

{{基于肾素-血管紧张素系统的抗高血压药}}

[[Category:血管紧张素转化酶抑制剂|Category:血管紧张素转化酶抑制剂]]
[[Category:乙酯|Category:乙酯]]
[[Category:酰胺|Category:酰胺]]
[[Category:羧酸|Category:羧酸]]
[[Category:咪唑啉酮|Category:咪唑啉酮]]